Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday.

Two new compounds have been discovered that could pave the wayfor a new class of HIV drugs, according to scientists at TheScripps Research Institute.Here is the press release. I haveboldfacedsome ...

The 12th Retrovirus Conference heard the results of the first dosing trials to give people with HIV two completely new classes of drugs – maturation inhibitors and integrase inhibitors. Although both ...

Two new classes of HIV drugs are poised to hit the market in 2007, signalling what many say is a watershed in HIV treatment, second only to the introduction of cocktail therapy more than a decade ago.

HIV drugs that are in the same class stop the replication of HIV in the same way. This means if you become resistant to one drug in a certain class, you might be fully or partly resistant to other ...

A new class of anti-HIV drug which inhibits an as-yet untargeted enzyme in the virus has proven effective in a drug trial, according to an Article in this week's edition of the Lancet.

The new drugs represent a whole new approach to fighting the disease. The most commonly used drugs on the market today target the HIV virus once it has already invaded immune-system cells called CD4s.

LA JOLLA, Calif., Feb. 4 (UPI) -- U.S. scientists say they've discovered two compounds that might lay the foundation for the development of a new class of anti-HIV drugs.

A cohort of people with HIV who took NRTIs (a class of HIV drugs) as part of HIV treatment showed lower rates of Alzheimer’s disease than people without HIV. The team of American researchers behind ...

ViiV files its rescue therapy for multidrug resistant HIV in Europe, a few weeks after applying for US approval. Analysts have tipped fostemsavir to make around $400m a year at peak ...

New research indicates that an experimental HIV drug could help treat or prevent AIDS with just two doses per year. A paper published Wednesday in the journal Nature suggests that the experimental ...